Daiichi Sankyo - Latest News and Information
4568
Daiichi Sankyo is a global pharmaceutical company focused on researching, developing, and bringing medicines to patients across multiple therapeutic areas. The company emphasizes pipelines in areas such as oncology and cardiovascular diseases, and engages in open innovation and clinical trial transparency to advance medical science. With operations and research activities spanning international markets, Daiichi Sankyo aims to improve patient outcomes through innovative therapies and responsible governance.
Hims & Hers Expands Personalized Digital Healthcare Platform
FDA Lifts Partial Hold on Merck, Daiichi's Phase 3 Lung Cancer Study
HER2’s Digital Rebirth Is Unlocking the Full Potential of ADCs
EU Starts Review of First-Line Enhertu for Breast Cancer
Building a Smart Oncology Pipeline with Cumulus Oncology
A New Approach to Drugging MYC: The Application of Translation-Inhibiting Interdictors To MYC-Driven Malignancies
Blocking the IgG Highway: FcRn Biology, Approved Agents, and the Small Molecule Horizon
FDA Knocks Back AstraZeneca's Self-Injected Lupus Drug
Ex-Novartis CMO John Tsai Joins Daiichi Sankyo
Targeting NLRP3: DFV890 and Beyond
12 Most Profitable Blue Chip Stocks to Invest In Now
2025 Novel Large Molecule FDA Drug Approvals
Lung Cancer Trial to Proceed After FDA Releases Hold on Merck, Daiichi’s ADC
Geoff McDonough's Big Plans for NodThera's NLRP3; Enhertu Leader Steps Down at Daiichi
Daiichi Ends Work on an ADC; Layoffs at GSK's R&D Unit
2025 Novel Small Molecule FDA Drug Approvals
The Top 12 Companies Hiring in Biopharma Now
No recent deals for this company.
